Results 171 to 180 of about 94,212 (236)
Engineered virus-hunter vaccine overcomes HBV immune tolerance. [PDF]
Chen X +21 more
europepmc +1 more source
Beyond diabetes and obesity: GLP-1 receptor agonists as multifunctional therapeutics across the steatotic liver disease spectrum. [PDF]
Mahalingam S +3 more
europepmc +1 more source
Major histocompatibility complex class I chain-related A and B molecules and their potential role in virus-associated cancers. [PDF]
Bouayad A.
europepmc +1 more source
Plasmepsins as Antimalarial Drug Targets—Then, Now, and the Future
ABSTRACT Malaria is a devastating disease caused by Plasmodium parasites. Plasmodium parasites express ten cathepsin D‐like aspartyl proteases, called plasmepsins (PMs). These PMs have diverse roles fulfill diverse functions throughout the parasite's lifecycle, though several exhibit functional redundancies. Among them, PMV, PMIV, and PMX are essential
Brad E. Sleebs
wiley +1 more source
Prohibitins: emerging host targets of bacteria and viruses at the plasma membrane, mitochondria, and cytoplasm. [PDF]
Rivera-Palomino GO, Theiss AL.
europepmc +1 more source
In patients with acute‐on‐chronic liver failure (ACLF), esophagogastric variceal bleeding (EGVB) represents a critical complication associated with high short‐term mortality. This study evaluated the efficacy of endoscopic treatment in this specific population and identified prognostic factors associated with 6‐week rebleeding and mortality.
Yanan Sun +7 more
wiley +1 more source
From legacy to innovation: A comprehensive review of vaccine platforms against viral infections. [PDF]
Farsiu N +8 more
europepmc +1 more source
Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao +4 more
wiley +1 more source

